Apolipoprotein A-IV concentrations and cancer in a large cohort of chronic kidney disease patients : results from the GCKD study
© 2024. The Author(s)..
BACKGROUND: Chronic kidney disease (CKD) is highly connected to inflammation and oxidative stress. Both favour the development of cancer in CKD patients. Serum apolipoprotein A-IV (apoA-IV) concentrations are influenced by kidney function and are an early marker of kidney impairment. Besides others, it has antioxidant and anti-inflammatory properties. Proteomic studies and small case-control studies identified low apoA-IV as a biomarker for various forms of cancer; however, prospective studies are lacking. We therefore investigated whether serum apoA-IV is associated with cancer in the German Chronic Kidney Disease (GCKD) study.
METHODS: These analyses include 5039 Caucasian patients from the prospective GCKD cohort study followed for 6.5 years. Main inclusion criteria were an eGFR of 30-60 mL/min/1.73m2 or an eGFR > 60 mL/min/1.73m2 in the presence of overt proteinuria.
RESULTS: Mean apoA-IV concentrations of the entire cohort were 28.9 ± 9.8 mg/dL (median 27.6 mg/dL). 615 patients had a history of cancer before the enrolment into the study. ApoA-IV concentrations above the median were associated with a lower odds for a history of cancer (OR = 0.79, p = 0.02 when adjusted age, sex, smoking, diabetes, BMI, albuminuria, statin intake, and eGFRcreatinine). During follow-up 368 patients developed an incident cancer event and those with apoA-IV above the median had a lower risk (HR = 0.72, 95%CI 0.57-0.90, P = 0.004). Finally, 62 patients died from such an incident cancer event and each 10 mg/dL higher apoA-IV concentrations were associated with a lower risk for fatal cancer (HR = 0.62, 95%CI 0.44-0.88, P = 0.007).
CONCLUSIONS: Our data indicate an association of high apoA-IV concentrations with reduced frequencies of a history of cancer as well as incident fatal and non-fatal cancer events in a large cohort of patients with CKD.
| Errataetall: |
ErratumIn: BMC Cancer. 2024 Mar 19;24(1):348. - PMID 38504160 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
BMC cancer - 24(2024), 1 vom: 07. März, Seite 320 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kollerits, Barbara [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Apolipoprotein A-IV |
|---|
| Anmerkungen: |
Date Completed 11.03.2024 Date Revised 20.03.2024 published: Electronic ErratumIn: BMC Cancer. 2024 Mar 19;24(1):348. - PMID 38504160 Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12885-024-12053-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369441583 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369441583 | ||
| 003 | DE-627 | ||
| 005 | 20240320234623.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240308s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12885-024-12053-8 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1337.xml |
| 035 | |a (DE-627)NLM369441583 | ||
| 035 | |a (NLM)38454416 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kollerits, Barbara |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Apolipoprotein A-IV concentrations and cancer in a large cohort of chronic kidney disease patients |b results from the GCKD study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.03.2024 | ||
| 500 | |a Date Revised 20.03.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a ErratumIn: BMC Cancer. 2024 Mar 19;24(1):348. - PMID 38504160 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a BACKGROUND: Chronic kidney disease (CKD) is highly connected to inflammation and oxidative stress. Both favour the development of cancer in CKD patients. Serum apolipoprotein A-IV (apoA-IV) concentrations are influenced by kidney function and are an early marker of kidney impairment. Besides others, it has antioxidant and anti-inflammatory properties. Proteomic studies and small case-control studies identified low apoA-IV as a biomarker for various forms of cancer; however, prospective studies are lacking. We therefore investigated whether serum apoA-IV is associated with cancer in the German Chronic Kidney Disease (GCKD) study | ||
| 520 | |a METHODS: These analyses include 5039 Caucasian patients from the prospective GCKD cohort study followed for 6.5 years. Main inclusion criteria were an eGFR of 30-60 mL/min/1.73m2 or an eGFR > 60 mL/min/1.73m2 in the presence of overt proteinuria | ||
| 520 | |a RESULTS: Mean apoA-IV concentrations of the entire cohort were 28.9 ± 9.8 mg/dL (median 27.6 mg/dL). 615 patients had a history of cancer before the enrolment into the study. ApoA-IV concentrations above the median were associated with a lower odds for a history of cancer (OR = 0.79, p = 0.02 when adjusted age, sex, smoking, diabetes, BMI, albuminuria, statin intake, and eGFRcreatinine). During follow-up 368 patients developed an incident cancer event and those with apoA-IV above the median had a lower risk (HR = 0.72, 95%CI 0.57-0.90, P = 0.004). Finally, 62 patients died from such an incident cancer event and each 10 mg/dL higher apoA-IV concentrations were associated with a lower risk for fatal cancer (HR = 0.62, 95%CI 0.44-0.88, P = 0.007) | ||
| 520 | |a CONCLUSIONS: Our data indicate an association of high apoA-IV concentrations with reduced frequencies of a history of cancer as well as incident fatal and non-fatal cancer events in a large cohort of patients with CKD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Apolipoprotein A-IV | |
| 650 | 4 | |a Cancer | |
| 650 | 4 | |a Inflammation | |
| 650 | 4 | |a Kidney function | |
| 650 | 4 | |a Prospective study | |
| 650 | 7 | |a apolipoprotein A-IV |2 NLM | |
| 650 | 7 | |a Apolipoproteins A |2 NLM | |
| 700 | 1 | |a Gruber, Simon |e verfasserin |4 aut | |
| 700 | 1 | |a Steinbrenner, Inga |e verfasserin |4 aut | |
| 700 | 1 | |a Schwaiger, Johannes P |e verfasserin |4 aut | |
| 700 | 1 | |a Weissensteiner, Hansi |e verfasserin |4 aut | |
| 700 | 1 | |a Schönherr, Sebastian |e verfasserin |4 aut | |
| 700 | 1 | |a Forer, Lukas |e verfasserin |4 aut | |
| 700 | 1 | |a Kotsis, Fruzsina |e verfasserin |4 aut | |
| 700 | 1 | |a Schultheiss, Ulla T |e verfasserin |4 aut | |
| 700 | 1 | |a Meiselbach, Heike |e verfasserin |4 aut | |
| 700 | 1 | |a Wanner, Christoph |e verfasserin |4 aut | |
| 700 | 1 | |a Eckardt, Kai-Uwe |e verfasserin |4 aut | |
| 700 | 1 | |a Kronenberg, Florian |e verfasserin |4 aut | |
| 700 | 0 | |a GCKD Investigators |e verfasserin |4 aut | |
| 700 | 1 | |a Schneider, Markus P |e investigator |4 oth | |
| 700 | 1 | |a Schiffer, Mario |e investigator |4 oth | |
| 700 | 1 | |a Prokosch, Hans-Ulrich |e investigator |4 oth | |
| 700 | 1 | |a Bärthlein, Barbara |e investigator |4 oth | |
| 700 | 1 | |a Beck, Andreas |e investigator |4 oth | |
| 700 | 1 | |a Reis, André |e investigator |4 oth | |
| 700 | 1 | |a Ekici, Arif B |e investigator |4 oth | |
| 700 | 1 | |a Becker, Susanne |e investigator |4 oth | |
| 700 | 1 | |a Alberth-Schmidt, Ulrike |e investigator |4 oth | |
| 700 | 1 | |a Weigel, Anke |e investigator |4 oth | |
| 700 | 1 | |a Marschall, Sabine |e investigator |4 oth | |
| 700 | 1 | |a Schefler, Eugenia |e investigator |4 oth | |
| 700 | 1 | |a Walz, Gerd |e investigator |4 oth | |
| 700 | 1 | |a Köttgen, Anna |e investigator |4 oth | |
| 700 | 1 | |a Schultheiß, Ulla T |e investigator |4 oth | |
| 700 | 1 | |a Meder, Simone |e investigator |4 oth | |
| 700 | 1 | |a Mitsch, Erna |e investigator |4 oth | |
| 700 | 1 | |a Reinhard, Ursula |e investigator |4 oth | |
| 700 | 1 | |a Floege, Jürgen |e investigator |4 oth | |
| 700 | 1 | |a Saritas, Turgay |e investigator |4 oth | |
| 700 | 1 | |a Gross, Alice |e investigator |4 oth | |
| 700 | 1 | |a Schaeffner, Elke |e investigator |4 oth | |
| 700 | 1 | |a Baid-Agrawal, Seema |e investigator |4 oth | |
| 700 | 1 | |a Theisen, Kerstin |e investigator |4 oth | |
| 700 | 1 | |a Haller, Hermann |e investigator |4 oth | |
| 700 | 1 | |a Zeier, Martin |e investigator |4 oth | |
| 700 | 1 | |a Sommerer, Claudia |e investigator |4 oth | |
| 700 | 1 | |a Aykac, Mehtap |e investigator |4 oth | |
| 700 | 1 | |a Wolf, Gunter |e investigator |4 oth | |
| 700 | 1 | |a Busch, Martin |e investigator |4 oth | |
| 700 | 1 | |a Steiner, Andy |e investigator |4 oth | |
| 700 | 1 | |a Sitter, Thomas |e investigator |4 oth | |
| 700 | 1 | |a Krane, Vera |e investigator |4 oth | |
| 700 | 1 | |a Börner-Klein, Antje |e investigator |4 oth | |
| 700 | 1 | |a Bauer, Britta |e investigator |4 oth | |
| 700 | 1 | |a Oefner, Peter |e investigator |4 oth | |
| 700 | 1 | |a Gronwald, Wolfram |e investigator |4 oth | |
| 700 | 1 | |a Schmid, Matthias |e investigator |4 oth | |
| 700 | 1 | |a Nadal, Jennifer |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t BMC cancer |d 2001 |g 24(2024), 1 vom: 07. März, Seite 320 |w (DE-627)NLM111431948 |x 1471-2407 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2024 |g number:1 |g day:07 |g month:03 |g pages:320 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12885-024-12053-8 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2024 |e 1 |b 07 |c 03 |h 320 | ||